斯派格拉斯制药
SGP
24.00
-0.72
-2.91%
斯派格拉斯制药
US · SGP
#3415 按市值排名
上市于 2026
24.00
-0.72
-2.91%
实时 - 追踪5344个代码 - 心跳于494秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 94.63% -0.02pp
- 机构数量
- 69
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund76.30%
Mutual Fund12.38%
Hedge Fund5.73%
Individual/Insider4.28%
Public Company0.14%
Other1.09%
主要股东 截至 2026-06-30
RA Capital Management, L.P.
23.98% · 8.02M 股
New Enterprise Associates, Inc.
22.10% · 7.39M 股
Vensana Capital Management, LLC
9.90% · 3.31M 股
Sands Capital Alternatives, LLC
7.47% · 2.50M 股
Gilde Healthcare Partners BV
6.54% · 2.19M 股
Samsara BioCapital LLC
6.31% · 2.11M 股
Malik Kahook
2.61% · 873.98K 股
BlackRock
2.13% · 711.71K 股
T. Rowe Price Group, Inc.
2.02% · 674.14K 股
Vestal Point Capital, LP
2.00% · 670.00K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪45份申报 · 21次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| RA Capital Management, L.P. | -- | 23.98% |
| New Enterprise Associates, Inc. | -- | 22.10% |
| Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | 2.61% |
| Bilal Khan | Independent Director | 0.83% |
| Patrick Mooney | Chief Executive Officer | 0.55% |
| James Dennewill | Chief Operating Officer | 0.29% |
| Scott Sandell | -- | -- |
| Geoffrey Pardo | Independent Director | -- |
| Mohamad Makhzoumi | -- | -- |
| Elizabeth O'Farrell | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-02-08 | New Enterprise Associates, Inc. | -- | Private Acquisition | +937,500 | $16.00 |
| 2026-02-08 | New Enterprise Associates, Inc. | -- | Derivative Exercise and Retained | +6,454,801 | -- |
| 2026-02-08 | RA Capital Management, L.P. | -- | Private Acquisition | +3,690,000 | $16.00 |
| 2026-02-08 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +4,331,117 | -- |
| 2026-02-08 | Gilde Healthcare Partners BV | -- | Private Acquisition | +312,500 | $16.00 |
| 2026-02-08 | Gilde Healthcare Partners BV | -- | Derivative Exercise and Retained | +1,875,013 | -- |
| 2026-02-08 | Bilal Khan | Independent Director | Private Acquisition | +135,000 | $16.00 |
| 2026-02-04 | Scott Sandell | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Geoffrey Pardo | Independent Director | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | Mohamad Makhzoumi | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Elizabeth O'Farrell | -- | Other Derivative Acquisition | +13,700 | $16.00 |
| 2026-02-04 | Elizabeth O'Farrell | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | RA Capital Management, L.P. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Jean-Frederic Viret | Chief Financial Officer | Other Derivative Acquisition | +17,500 | $16.00 |
| 2026-02-04 | Jean-Frederic Viret | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Kirk Nielsen | -- | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | Michael Dybbs | Independent Director | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | Other Derivative Acquisition | +105,000 | $16.00 |
| 2026-02-04 | Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
斯派格拉斯制药 讨论区 0 条评论